25

Feb2020

Sharing Responses to the Patented Medicine Prices Review Board (PMPRB) Draft Guidelines Consultation

On November 21, 2019, the PMPRB published its draft Guidelines and launched a public consultation as a step towards implementing the recently amended Patented Medicines Regulations. Since then, the PMPRB has engaged with stakeholders to obtain feedback on its proposed pricing Guidelines. The consultation period closed on February 14, ... Read More

14

Feb2020

CADTH Releases Pharmaceutical Reviews Update – Issue 13

CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website. In this Pharmaceutical Reviews Update, CADTH made program updates ... Read More

13

Feb2020

PDCI Analysis Estimates Impact of PMPRB Draft Guidelines to be up to $41.8 Billion

Following the publication of the PMPRB Draft Guidelines on Nov 21, 2019, PDCI undertook an analysis to critically assess the impact of the PMPRB regulatory changes published in August 2019, as proposed to be implemented in the Draft Guidelines. Top-Line Summary The PMPRB regulatory changes and Draft ... Read More

29

Jan2020

PDCI’s New Associate Director, HTA and Clinical Evaluation

PDCI is excited to announce the promotion of Andrea Lau to the position of Associate Director, HTA and Clinical Evaluation. Andrea has been with PDCI for over 3 years, and in that time has been invaluable ... Read More

14

Jan2020

PMPRB and “Zero-dollar” Sales

W. Neil Palmer In its December 2019 NEWSletter[1], the Patented Medicine Prices Review Board (PMPRB) is “reminding” patentees that they are required under the Patent Act (the Act) and the Patented Medicines Regulations (the Regulations) to file all zero-dollar sales, referring specifically to free goods. This “reminder” is troubling ... Read More

18

Dec2019

Happy Holidays from PDCI Market Access!

26

Nov2019

PDCI Market Access: PMPRB Reforms Briefing and Strategy Sessions (Toronto and Montreal)

REGISTRATION IS OPEN! Learn how the new PMPRB amendments and guidelines will affect your pharmaceutical pricing, negotiations and reimbursement Join PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, for industry-only sessions on the pricing guidelines, led by senior members ... Read More

21

Nov2019

WHITEPAPER: Debunking Price Regulations Based on the Pharmacoeconomic Value Factor

Pricing changes for Canada’s patented medicines are on their way and stakeholders are anticipating the release of the updated guidelines. How will the guidelines be operationalized? How will the new pharmacoeconomic factors be implemented? In an effort to answer these questions, PDCI has attempted to reverse-engineer the proposed Pharmacoeconomic Value ... Read More

31

Oct2019

INFOGRAPHIC: The Truth About the Federal Drug Pricing Reform

3Sixty Public Affairs and PDCI Market Access have collaborated to create an infographic that unmasks the reality behind the assumptions Health Canada has used to justify its ongoing drug pricing reforms (through the Patented Medicine Prices Review Board). When it comes to federal drug pricing reform in Canada, there is ... Read More

25

Oct2019

Keeley Farrell Joins PDCI Market Access!

PDCI is very pleased to welcome Keeley Farrell to the PDCI Team as Analyst, HTA and Clinical Evaluation. Keeley will help to support the development and preparation of the evidence-based clinical components of reimbursement and pricing submissions. She will also conduct research to support market access and ... Read More